Update of Clostridium Difficile Infection Due to PCR Ribotype 027 in Europe, 2008 by Drudy, Denise et al.
Technological University Dublin 
ARROW@TU Dublin 
Articles School of Biological Sciences 
2008 
Update of Clostridium Difficile Infection Due to PCR Ribotype 027 
in Europe, 2008 
Denise Drudy 
Technological University Dublin, denise.drudy@tudublin.ie 
E. J. Kuijper 
Leiden University Medical Center 
F. Barbut 
Saint-Antoine Hospital, Paris, France 
J. S. Brazier 
University Hospital of Wales, Cardiff, 
Follow this and additional works at: https://arrow.tudublin.ie/scschbioart 
 Part of the Biology Commons 
Recommended Citation 
Drudy, D. et al (2008) Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. 
Eurosurveillance. 13 (31),p.18942. doi:10.21427/D7KS6P 
This Article is brought to you for free and open access by 
the School of Biological Sciences at ARROW@TU Dublin. 
It has been accepted for inclusion in Articles by an 
authorized administrator of ARROW@TU Dublin. For more 
information, please contact 
yvonne.desmond@tudublin.ie, arrow.admin@tudublin.ie, 
brian.widdis@tudublin.ie. 
This work is licensed under a Creative Commons 
Attribution-Noncommercial-Share Alike 3.0 License 
  EUROSURVEILLANCE  Vol .  13 ·  Issues 7–9 ·  Jul–Sep 2008 ·  www.eurosurveillance.org 1
E uro roun dups
U p d at e  o f  C lo s t r i d i u m  d i f f i C i l e  i n f e c t i o n  d U e  to  p c R 
R i b ot y p e  027  i n  e U R o p e ,  2008
E J Kuijper (ejkuijper@gmail.com)1, F Barbut2, J S Brazier3, N Kleinkauf4, T Eckmanns4, M L Lambert5, D Drudy6, F Fitzpatrick7, 
C Wiuff8, D J Brown9, J E Coia9, H Pituch10, P Reichert11, J Even11, J Mossong11, A F Widmer12, K E Olsen13, F Allerberger14, 
D W Notermans15, M Delmée16, B Coignard17, M Wilcox18, B Patel19, R Frei20, E Nagy21, E Bouza22, M Marin10, T Åkerlund23, 
A Virolainen-Julkunen24, O Lyytikäinen24, S Kotila24, A Ingebretsen25, B Smyth26, P Rooney27, I R Poxton28, D. L. Monnet29
1. National Reference Laboratory for Clostridium difficile. Leiden University Medical Center, Leiden, The Netherlands
2. National Reference Center for Clostridium difficile, Saint-Antoine Hospital, Paris, France
3. Anaerobe Reference Laboratory, National Public Health Service for Wales Cardiff, University Hospital of Wales, Cardiff, 
United Kingdom
4. Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
5. Epidemiology Unit, Scientific Institute of Public Health, Brussels, Belgium
6. Centre for Food Safety, Food Science and Veterinary Medicine, University College Dublin, Dublin, Ireland
7. Health Protection Surveillance Centre and Beaumont Hospital, Dublin, Ireland
8. Health Protection Scotland, Section for Healthcare Associated Infection and Infection Control, Glasgow, United Kingdom
9. Scottish Clostridium difficile Reference Service, Stobhill Hospital, Glasgow, United Kingdom
10. Department of Medical Microbiology, Medical University of Warsaw, Warsaw, Poland
11. Division of Microbiology, National Public Health Laboratory, Luxembourg
12. Division of Infectious diseases and Hospital Epidemiology, University Hospital, Basel, Switzerland
13. National Reference Laboratory for Enteropathogens, Statens Serum Institut, Copenhagen, Denmark
14. Österreichische Agentur für Gesundheit und Ernährungssicherheit (Austrian Agency for Health and Food Safety; AGES), 
Vienna, Austria
15. Centrum Infectieziektebestrijding (Centre for Infectious Disease Control; CIb), Rijksinstituut voor Volksgezondheid en 
Milieu (National Institute for Public Health and the Environment; RIVM), Bilthoven, The Netherlands
16. Microbiology Department, Saint-Luc University Hospital, Brussels, Belgium
17. Departement of Infectious Diseases, Institut de Veille Sanitaire (National Public Health Institute; InVS), Saint-Maurice, France 
18. Clostridium difficile Ribotyping Network for England (CDRNE), Health Protection Agency, Reference Leeds General Infirmary, 
Leeds, United Kingdom
19. 0 Health Protection Agency, London, United Kingdom
20. Microbiology Laboratory, University Hospital, Basel, Switzerland
21. Department of Clinical Microbiology, Faculty of Medicine, University of Szeged, Szeged, Hungary
22. Department of Medical Microbiology, University General Hospital Gregorio Maranon, Madrid, Spain
23. Smittskyddsinstitutet (Swedish Institute for Infectious Disease Control; SMI), Solna, Sweden
24. Kansanterveyslaitos (National Public Health Institute; KTL), Helsinki, Finland
25. Department of Infection Prevention, Rikshospitalet, Oslo, Norway
26. Health Protection Agency, Communicable Disease Surveillance Centre (Northern Ireland), Belfast, United Kingdom
27. Microbiology Laboratory Belfast City Hospital, Belfast, United Kingdom
28. Medical Microbiology, Centre for Infectious Diseases, University of Edinburgh College of Medicine and Veterinary Medicine, 
Edinburgh, United Kingdom
29. European Centre for Disease Prevention and Control, Stockholm, Sweden
Outbreaks of Clostridium difficile infections (CDI) with increased 
severity, high relapse rate and significant mortality have been 
related to the emergence of a new, hypervirulent C. difficile strain 
in North America and Europe. This emerging strain is referred to 
as PCR ribotype 027 (Type 027). Since 2005, individual countries 
have developed surveillance studies about the spread of type 027. 
C. difficile Type 027 has been reported in 16 European countries. It 
has been responsible for outbreaks in Belgium, Germany, Finland, 
France, Ireland, Luxembourg, The Netherlands, Switzerland and the 
United Kingdom (England, Wales, Northern Ireland and Scotland). 
It has also been detected in Austria, Denmark, Sweden, Norway, 
Hungary, Poland and Spain. Three countries experienced imported 
patients with CDI due to Type 027 who acquired the infection abroad. 
The antimicrobial resistance pattern is changing, and outbreaks 
due to clindamycin-resistant ermB positive Type 027 strains have 
occurred in three European countries. Ongoing epidemiological 
surveillance of cases of CDI, with periodic characterisation of the 
strains involved, is required to detect clustering of cases in time 
and space and to monitor the emergence of new, highly virulent 
clones. 
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Introduction
Since the emergence of a new virulent strain of Clostridium 
difficile characterised as toxinotype III, North American pulsed-
field type 1 (NAP1), restriction-endonuclease analysis group type 
BI and PCR-ribotype 027 (Type 027), multiple outbreaks have 
been reported in North America and Europe [1-9]. The increased 
virulence of C. difficile Type 027 is thought to be associated with 
a 1 base pair deletion at position 117 of the tcdC gene which 
leads to an increased or prolonged production of toxins A and B, 
and possibly the production of a binary toxin [1-3]. However, these 
virulence factors are not unique for Type 027 and are also present 
in other PCR ribotypes.
The first reports of outbreaks of C. difficile infections (CDI) due 
to Type 027 came from Canada, and the province of Quebec was 
the one affected first and most severely  [4]. In the United States, 
cases of C. difficile Type 027 infection have been reported from 
at least 38 states (http://www.cdc.gov/ncidod/dhqp/id_Cdiff.html), 
and surveillance of community-acquired CDI has started [10]. By 
2007, C. difficile Type 027 had been detected in 11 European 
countries [9]. The present report is an update on the situation in 
Europe in 2008. 
Surveillance efforts
In 2005, the European Study Group for Clostridium difficile 
(ESGCD) performed a two-month surveillance study in 38 hospitals 
from 14 European countries [5]. Unfortunately, only hospital-
acquired CDI were studied and no precise information on the 
severity and outcome was collected. The mean incidence of CDI 
was 2.45 +/-1.8 cases per 10,000 patient-days. The distribution 
of PCR ribotypes varied among hospitals and countries. Of 322 
toxinogenic isolates, 20 (6.2%) belonged to Type 027 and were 
reported from Ireland, Belgium and The Netherlands. Patients 
infected with Type 027 were more likely to have a more severe 
disease, and to have been treated by metronidazole or vancomycin 
compared to patients infected by another PCR ribotype.
The European Centre for Disease Prevention and Control (ECDC) 
recognised this emerging new disease and undertook several actions 
to inform all European Union (EU) Member States. ECDC also 
offered support for surveillance studies at national and European 
level. Another pan-European surveillance study is presently being 
organised, which will collect epidemiological and microbiological 
data for one month in a selected number of hospitals from all EU 
Member States in order to estimate the incidence of hospital-
acquired as well as community-acquired CDI. The results of this 
study are expected to be available in 2009.
Austria
In Austria, C. difficile Type 027 was reported once in 2006 in 
a British tourist suffering from pseudomembranous colitis. In May 
2008, two cases of CDI due to Type 027 were found in patients 
who had no travel history in the year before their hospitalisation 
[11]. Typing patterns of isolates submitted voluntarily since 2006 
demonstrate the occurrence of non-027 clusters of CDI cases in 
Austrian hospitals. The largest cluster affected a tertiary teaching 
hospital in 2006, where C. difficile PCR ribotype 053 represented 
10 of 21 CDI cases. CDI is not a reportable disease in Austria. 
Hospital discharge data indicate a significant increase of CDI during 
the last years, from 777 cases (54 deaths) in 2003 to 997 cases 
(80 deaths) in 2004, 1,453 cases (88 deaths) in 2005 and 2,192 
cases (150 deaths) in 2006.
Belgium
In Belgium, laboratory-based surveillance of CDI clusters 
performed by the national reference laboratory at the Université 
Catholique de Louvain as well as prospective surveillance of CDI 
incidence in acute care hospitals monitored by the Institute for 
Public Health were initiated in January 2006. Surveillance of CDI 
has become a legal obligation since July 2007. In 2007, 896 C. 
difficile isolates were analysed at the reference laboratory. 
With 17.6% (158 isolates) Type 027 was the most frequently 
found type. Other frequently found types were PCR ribotypes 
078 and 031, accounting for 6.3% and 5.6% of these isolates, 
respectively. Overall, the mean (median) incidence of CDI was 
1.7 (1.6) cases per 1,000 admissions and 2.07 (1.86) cases per 
10,000 hospital days. Sixty-eight percent of these cases occurred 
more than two days after hospital admission. 
Denmark
In April 2006, Statens Serum Institut encouraged the Danish 
departments of clinical microbiology to report C. difficile cases on 
a continuous basis and to forward isolates for characterisation in 
cases of severe disease or in outbreak situations. In a retrospective 
survey covering a county in Region South Denmark, a cluster of 
eight patients with C. difficile Type 027 was detected. The isolates 
were recovered from 22 faecal samples that had been collected 
between November 2006 and March 2007. All eight cases were 
hospitalised in two hospitals in the region. Subsequently, active 
surveillance was initiated in the same region for the period June-
August 2007, which resulted in five additional Type 027 cases 
among 22 C. difficile isolates tested. Interestingly, all 13 isolates 
were resistant to newer fluoroquinolones and cephalosporins, but 
susceptible to erythromycin and clindamycin. 
Finland
The first case of C. difficile Type 027-associated disease was 
detected in Finland in October 2007 [12]. Since then the National 
Public Health Institute (Kansanterveyslaitos; KTL) has intensified 
surveillance and control of CDI. A few additional cases caused 
by Type 027 were detected retrospectively, indicating that this 
strain had previously been circulating in Finland. The Finnish 
Hospital Infection Programme (SIRO) prepared a protocol for CDI 
surveillance to detect severe cases and epidemics caused by C. 
difficile. Molecular methods for rapid detection of C. difficile Type 
027 were set up at two clinical, university-affiliated laboratories 
in Helsinki and Turku, and genotyping methods for molecular 
epidemiology of C. difficile were set up at KTL. 
During the five-month-period from mid-October 2007 to mid-
March 2008, isolates of C. difficile Type 027 were reported from four 
of the nine health care districts that had sent the isolates to KTL, 
and originated from over 20 different health care facilities – most of 
them providing primary or long term care – located in southern and 
south-western Finland. Of the 268 isolates, 131 (49%) belonged 
to Type 027. The remaining isolates were distributed among more 
than 30 different PCR ribotypes. 
France
In France, the CDI surveillance is based on the mandatory 
notification of severe cases or outbreaks of CDI to local health 
departments, regional infection control coordinating centres and 
the National Institute for Public Health (Institut de Veille Sanitaire; 
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InVS). Laboratories are encouraged to send the isolates from 
notified cases to a network of six French reference laboratories 
for C. difficile. 
In April 2006, the first cluster of C. difficile Type 027 was 
reported in Northern France. From January 2006 to December 
2007, 214 health care facilities reported at least one severe case 
or outbreak of CDI and a total of 1,247 cases. Sixty-four health care 
facilities (29 in 2006 and 35 in 2007, with no overlap between 
these 64) were affected by Type 027. Most cases originated from 
healthcare facilities in the Nord Pas-de-Calais region, but in 2007, 
small clusters of C. difficile Type 027 were reported from three 
other French regions, Picardie, Rhône-Alpes and Lorraine. Among 
the 1,227 isolates (511 in 2006 and 716 in 2007) sent for 
typing, 337 (27.5%) were identified as Type 027 (212 in 2006, 
i.e. 41.5% of the typed isolates, and 125 in 2007, i.e. 17.4% of 
the typed isolates). The large majority of strains were resistant to 
erythromycin and moxifloxacin, but susceptible to clindamycin. 
However, one hospital in Picardie reported an outbreak associated 
with a clindamycin-resistant strain that tested positive for the ermB 
gene encoding the macrolide-lincosamide-streptogramin B (MLSB) 
phenotype.  
Unfortunately, no data are available on the occurrence of other 
PCR ribotypes. 
Germany
Since October 2007, it is mandatory to report severe cases of 
CDI to the local authorities. Patient-based notifications are done 
by the physician treating the patient. Severe CDI cases are defined 
as cases which necessitate readmission to a healthcare facility 
due to the relapse of CDI, admission to an intensive care unit 
for treatment of CDI or its complications, surgery (colectomy) for 
toxic megacolon, perforation or refractory colitis, or lead to death 
within 30 days after diagnosis of CDI, if CDI is either the primary 
or a contributive cause to death. This mandatory surveillance was 
implemented shortly after the first outbreak of C. difficile Type 
027 was detected in the region of Trier, Rhineland-Palatine in 
September 2007. To date, five of 16 Federal States (Länder), all 
of which are located in the south-west of Germany, have reported 
cases of CDI due to Type 027 [13,14].
Hungary (not included in the table)
A recently completed surveillance study in three different parts 
of Hungary revealed one isolate of Type 027 among 150 C. difficile 
isolates collected. The patient had systemic lupus erythematosus 
and developed severe CDI after antibiotic treatment for pneumonia 
in a hospital in Budapest.  
 
Ireland
After the first report of C. difficile Type 027 in Ireland in 2007, 
this type was identified in six additional healthcare settings [15,16]. 
To date, more than 100 C. difficile Type 027 isolates from Ireland 
have been characterised by toxinotyping and 16-23S PCR ribotyping 
[15]. Isolates from two healthcare settings were susceptible to 
clindamycin (n=11: MIC90=4 mg/l). However, clindamycin-resistant 
Type 027 isolates (n=96, MIC90>256 mg/l) were identified in the 
five other healthcare institutions. All clindamycin-resistant Type 27 
isolates tested positive for the ermB gene. Multiple locus variable 
number tandem repeat (MLVA) typing could clearly differentiate 
between clindamycin-resistant and -susceptible isolates from the 
same geographical region and sub-grouped them into two distinct 
clusters, with all isolates from the clindamycin-resistant cluster 
being were closely related [16]. 
CDI has become a notifiable disease in the Republic of Ireland 
since May 2008 under ‘acute infectious gastroenteritis’ using 
the case definition by ESGCD and ECDC. Only new cases will be 
reported, and this will enable data to be collected on the national 
level, but not on hospital-level. There are moves to make CDI 
notifiable in its own right to enable the collection of enhanced 
surveillance data (e.g. on origin and onset of CDI). National 
guidelines on surveillance, diagnosis and management of C. difficile 
have been published in May 2008 [17].
Luxembourg
During the period between October 2006 (start of CDI surveillance 
in Luxembourg) and February 2008, 96 (26%) of 368 submitted 
C. difficile strains were PCR ribotyped as Type 027. Type 027 was 
the type found most frequently, followed by types 001 and 106, but 
confirmation for the latter two is pending. The isolates came from 
all 10 hospitals in Luxembourg. The situation is ongoing and the 
total number of C. difficile isolates is now exceeding the number 
of salmonella and campylobacter isolates. 
The median age significantly differed between patients with 
Type 027 (74 years) and patients with other ribotypes (59 years) 
(p=0.001). The mortality rate of CDI due to Type 027 within one 
month and within three months of isolate referral was 14.8% and 
21.0%, respectively. In a logistic regression model, one-month 
mortality of CDI was significantly associated with age over 70 
years (p<0.0001), but not with gender (p=0.66) or PCR ribotype 
(p=0.14).
Netherlands
Since October 2005, the Centre for Infectious Disease Control 
(CIb) at the National Institute for Public Health and the Environment 
(Rijks Instituut voor Volksgezondheid en Milieu; RIVM) and the 
reference laboratory for C. difficile at Leiden University Medical 
Center have encouraged microbiologists to send C. difficile isolates 
from patients with a severe course of CDI, or when an increased 
incidence of CDI was noticed. During the surveillance period from 
2005 to 2007, Type 027 was reported from an increasing number 
of healthcare facilities in an endemic form or in outbreaks. At the 
end of 2007, 35 healthcare facilities have been affected, compared 
to 22 healthcare facilities until the end of 2006 [8]. During the 
surveillance period of 2006/2007, five outbreaks with Type 027 
occurred, compared to 11 outbreaks in 2005/2006. One hospital 
was affected by an outbreak caused by both Type 027 and Type 
017. 
Comparison of clinical data of patients with CDI due to Type 
027 (n=128) and other types (n=443) showed that CDI due to Type 
027 was associated with older age, use of cephalosporins (mainly 
second generation) and fluoroquinolones (mainly ciprofloxacin). 
Patients with Type 027 CDI had more relapses and a more severe 
disease with a higher overall and attributable mortality [8]. C. 
difficile Type 027 was significantly more often acquired at a health 
care institution. Other frequently isolated PCR ribotypes in The 
Netherlands were types 014, 001 and 078. 
Norway
In December 2007, the first two cases of CDI due to Type 027 
in Norway were reported from a university hospital in Oslo [18]. 
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Surveillance and infection control measures did not reveal other 
Type 027 isolates at this hospital. In February 2008, a third case 
of CDI due to Type 027 was detected at a nursing home in Oslo. 
Since January 2008, the Department of Infection Prevention in 
cooperation with the Institute of Microbiology, both at Rikshospitalet 
University Hospital, Oslo, have performed genotypic characterisation 
of C. difficile. The most frequently found PCR ribotype is Type 014. 
Unfortunately, most medical microbiology laboratories in Norway 
do not cultivate C. difficile. As a consequence, the distribution of 
PCR ribotypes in Norway remains unknown.  
Poland
No systematic CDI surveillance has yet been developed in Poland. 
Between 2005 and 2007, a surveillance study was performed in 
four hospitals in the Mazovia region. Of 400 C. difficile isolates, 
one isolate belonged to Type 027. As determined by E-tests, the 
isolate was highly resistant to fluoroquinolones (ciprofloxacin, 
gatifloxacin and moxifloxacin, MIC≥32 mg/l) and erythromycin 
(MIC≥256 mg/l), but susceptible to clindamycin (MIC=6 mg/l), 
metronidazole (MIC=0.38 mg/l) and vancomycin (MIC=0.75 mg/l). 
The most frequent PCR ribotype was Type 017, which accounted 
for approximately 40% of the C. difficile isolates studied. 
Spain
Spain does not have a national surveillance programme to 
investigate cases of CDI or an official reference laboratory where 
hospitals could send C. difficile isolates for further characterisation. 
A surveillance study performed between January and June 2007 at 
a 1,750-bed, tertiary care hospital in Madrid revealed two cases of 
severe CDI due to Type 027. The index case was a Spanish patient 
admitted to the intensive care unit, who was transferred from a 
hospital in the United Kingdom. The other patient was a laboratory 
technician working with C. difficile isolates, who developed CDI 
shortly after antibiotic treatment. In this study, a non-specified PCR 
ribotype containing the genes for toxins A and B but not for the 
binary toxin, was detected in 103 of 388 typed C. difficile isolates 
(26.5%, 81 patients). 
Since the C. difficile Type 027 has the binary toxin genes, testing 
for the presence of these genes is performed for all C. difficile 
isolates. Binary toxin-positive strains are subsequently ribotyped. 
In contrast to previous studies performed in this hospital, there was 
an increase of non-027 C. difficile containing the genes for toxins A 
and B and the genes for the binary toxin (13% of the total number 
of isolates studied). The PCR ribotype pattern of the binary toxin 
positive isolates probably corresponds to Type 078. 
Sweden
Three sporadic ‘historical’ moxifloxacin-susceptible isolates 
of C. difficile Type 027 were found among 1,325 isolates 
collected between 1997 and 2001 in Sweden. In September 
2006, the Swedish Institute for Infectious Disease Control 
(Smittskyddsinstitutet; SMI) alerted microbiologists and clinicians 
about C. difficile Type 027 and laboratories were encouraged to 
send C. difficile isolates to SMI for microbiological characterisation 
for patients with a severe course of CDI or when an increased CDI 
incidence was noticed. 
Since epidemic Type 027 isolates have uniformly been 
moxifloxacin-resistant , a systematic screening of C. difficile 
isolates for moxifloxacin resistance was initiated during 2007 in 
four hospitals in Stockholm. In February 2008, this screening was 
extended to include all major hospitals in Sweden. Preliminary 
results indicate only one case of moxifloxacin-resistant Type 
027 (found in May 2008), but there is currently no indication of 
outbreaks due to C. difficile Type 027. The most frequently PCR 
ribotypes isolated in Sweden are Types 012 and 014. 
Switzerland
In Switzerland, the first outbreak of C. difficile Type 027 was 
observed in a geriatric hospital in Basel in 2006 [19]. The index 
case was an 82-year old female patient and the outbreak involved 
15 other patients between October 2006 and May 2007. It is 
likely that the index patient acquired C. difficile Type 027 during a 
hospital stay in a foreign country. The median age of the 16 patients 
was 83.5 years (interquartile range: 79-92 years). A severe to 
moderate course of CDI was reported in seven (44%) of the patients 
and crude mortality was 19% (three deaths). All isolates were highly 
resistant to moxifloxacin (MIC>32 mg/l), erythromycin (MIC>256 
mg/l) and clindamycin (MIC>256 mg/l). MLVA typing revealed one 
cluster of genetically highly related (STRD≤2) clindamycin-resistant 
Type 027 isolates which differed from the clindamycin-susceptible 
Type 027 control isolates and also from clindamycin-resistant 
isolates from Ireland. 
United Kingdom (UK)
In England and Wales, mandatory surveillance of CDI in patients 
over 65 years has been included in the healthcare-associated 
infection surveillance system for acute trusts [20]. This mandatory 
surveillance programme is operated by the Health Protection 
Agency (HPA) on behalf of the Department of Health. Through 
its network of regional laboratories in collaboration with the C. 
difficile Ribotyping Network for England (CDRNE) and the Anaerobe 
Reference Laboratory (ARL) in Cardiff, the HPA further obtains C. 
difficile isolates from symptomatic patients in a structured, but 
random sampling scheme. In England, 110 out of 145 hospitals 
(76%) investigated between April 2007 and February 2008 showed 
the presence of C. difficile Type 027. Of 2,084 C. difficile isolates, 
42% were typed as Type 027, 19% as Type 106 and 10% as Type 
001. In Wales, 10 out of 16 investigated hospitals showed the 
presence of C. difficile Type 027.  
In Scotland all diagnostic laboratories have been requested since 
September 2006 to submit C. difficile isolates to a UK reference 
laboratory in the case of severe CDI or outbreaks. The data are 
published quarterly [21]. Additionally, isolates from local research 
projects have also been submitted for ribotyping, which means that 
some hospitals/regions are over-represented in this collection of 
isolates. A total of 20 cases of C. difficile Type 027 were identified 
in Scotland in the period from September 2006 to April 2008. 
Among these were an outbreak with five cases in one hospital in the 
West of Scotland and an outbreak with three cases in a hospital in 
the North East of Scotland. In total, Type 027 has been detected 
in nine acute care hospitals in five different geographical regions 
of Scotland. One case was reported from a nursing home. 
Until recently, C. difficile Type 027 was not a common PCR 
ribotype in Scotland. With the two recent outbreaks the frequency 
of 027 has reached 5.7 %. Since 2006, the most frequent PCR 
ribotypes in Scotland have consistently been type 106 (55% of 
C. difficile isolates) and type 001 (21%). Four isolates of the new 
emerging ribotype 078 have been identified in Scotland as well.
In Northern Ireland, a survey was undertaken between September 
and December 2006, and 60 samples (4.0% of the annual total of C. 
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difficile reports) were ribotyped: the most common ribotypes were 
001 (35%), 106 (11.6%) and 078 (8.3%). Ribotype 027 was 
not identified in this small sample. The first report of ribotype 
027 in Northern Ireland related to a specimen in mid-June 2007. 
Since then there has been a large hospital outbreak associated with 
ribotype 027 (57 reports to date). 
An enhanced ribotyping surveillance programme has recently 
been established: 59 specimens were ribotyped, of which 35% 
were Type 078, 25% were Type 001 and 8% were Type 014/20. 
The sample contained two reports of Type 027 (3%). Compared 
with the earlier survey in 2006 there has been a marked increase in 
ribotype 078 and a decrease in ribotype 001. Further investigations 
are underway to analyse this change in ribotype incidence.
Conclusion
As of June 2008, C. difficile Type 027 has been reported from 
healthcare facilities in 16 European countries (Figure, Table). 
Among those, nine countries have reported outbreaks and seven 
countries have reported only sporadic cases. Because of the lack of 
national surveillance programmes in many countries, it is at present 
impossible to estimate the incidence of C. difficile Type 027 in 
Europe. A new, emerging Type 078 strain, with similar mechanisms 
for the hyper-production of toxins as Type 027, is increasingly 
reported in Belgium, The Netherlands, Northern Ireland, Scotland, 
and possibly Spain. 
The occurrence of outbreaks due to clindamycin-resistant Type 
027 isolates in three European countries is worrying. Clindamycin 
has been considered as a ‘protective’ antibiotic with regards to 
the development of CDI due to Type 027 [8]. However, resistance 
to clindamycin may increase the risk of CDI in patients receiving 
this agent and its use may be an important factor contributing to 
its persistence and spread. In addition, the report of erythromycin-
susceptible and clindamycin-susceptible Type 027 isolates in 
Germany and Denmark indicates that antimicrobial resistance 
patterns are very dynamic and can no longer be used to identify 
C. difficile Type 027. 
All European countries should now be aware about CDI in 
healthcare facilities, and specifically about C. difficile Type 027. 
Surveillance studies should be performed with uniform definitions, 
as proposed by ECDC [1]. These surveillance studies should not only 
focus on C. difficile Type 027, but include all major PCR ribotypes 
circulating in Europe since the distribution of these ribotypes varies 
greatly among European countries and over time.
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